Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14641422 | 0.85 | PTGS1 (0.41) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL1638487 | 0.80 | LMNA (0.38) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL14641423 | 0.80 | PTGS1 (0.38) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL27959803 | 0.79 | — | — | |
| SCHEMBL2231969 | 0.78 | TP53 (0.31) | LMNASLC6A6CYP2C19BLM | |
| SCHEMBL503109 | 0.78 | TP53 (0.31) | LMNASLC6A6CYP2C19BLM | |
| SCHEMBL4895410 | 0.78 | LMNA (0.36) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL2329583 | 0.78 | PTGS1 (0.36) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL11131287 | 0.76 | CA1 (0.39) | — | |
| SCHEMBL3795029 | 0.76 | PTGS1 (0.35) | LMNASLC6A6CYP2C19BLMAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030095924-A1 | Galenical formulations | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | US | disclosed |
| US-6364944-B1 | PYROLYSIS OF AN ORGANOSILICON COMPOUND TO PRODUCE A CARBON BLACK CONTAINING SILICON OXIDES AND SILICON CARBIDES | CABOT CORPORATION | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095924-A1 | Galenical formulations | GALR1, GALR2, LGALS1 | LMNA 759/4885SLC6A6 1041/4885CYP2C19 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.